Publicaciones en colaboración con investigadores/as de University of California, San Francisco (15)

2024

  1. Comparison of assays measuring extracellular vesicle tissue factor in plasma samples: communication from the ISTH SSC Subcommittee on Vascular Biology

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 10, pp. 2910-2921

  2. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

    The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

2023

  1. Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

    JCI Insight, Vol. 8, Núm. 2

  2. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

2022

  1. A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells

    Cell Metabolism, Vol. 34, Núm. 6, pp. 857-873.e9

  2. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

    Transplantation and Cellular Therapy, Vol. 28, Núm. 6, pp. 284-293

2021

  1. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

    Blood Cancer Journal, Vol. 11, Núm. 6

  2. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma

    Transplantation and Cellular Therapy, Vol. 27, Núm. 10, pp. 807-816

2019

  1. TGFb blockade enhances radiotherapy abscopal efficacy effects in combination with anti-PD1 and anti-CD137 immunostimulatory monoclonal antibodies

    Molecular Cancer Therapeutics, Vol. 18, Núm. 3, pp. 621-631

2018

  1. Bmi1-progenitor cell ablation impairs the angiogenic response to myocardial infarction

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 38, Núm. 9, pp. 2160-2173

2017

  1. BCL6 antagonizes NOTCH2 to maintain survival of human follicular lymphoma cells

    Cancer Discovery, Vol. 7, Núm. 5, pp. 506-521

  2. CREBBP inactivation promotes the development of HDAC3-dependent lymphomas

    Cancer Discovery, Vol. 7, Núm. 1, pp. 38-53

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2015

  1. Whole-genome fingerprint of the DNA methylome during human B cell differentiation

    Nature Genetics, Vol. 47, Núm. 7, pp. 746-756

2007

  1. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas

    Blood, Vol. 109, Núm. 1, pp. 271-280